Results 41 to 50 of about 3,679,356 (272)

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia

Haematologica, 2020
In older patients with acute myeloid leukemia, the more frequent presence of biologically inherent therapy-resistant disease and increased comorbidities translate to poor overall survival and therapeutic challenges. Optimal front-line therapies for older
Chetasi Talati, Varun C Dhulipala, Mar tine Extermann, Najla Al Ali, Jongphil Kim, Rami Komrokji, Kendra Sweet, Andrew Kuykendall, Marina Sehovic, Tea Reljic, Benjamin Djulbegovic, Jeffrey E. Lancet   +11 more
doaj   +1 more source

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia

Clinical Case Reports, 2023
Key Clinical Message Hypomethylating agents may be useful in some but not all cases of myelodysplastic syndromes. In some versions of these conditions, this treatment may yield deleterious results.
Anwarul Islam
doaj   +1 more source

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents

Blood Advances, 2022
Venetoclax, a small-molecule inhibitor of B-cell lymphoma-2, in combination with the hypomethylating agents (HMA) azacitidine or decitabine, is FDA-approved for elderly/un fi t patients with acute myeloid leukemia (AML).
I. Johnson, Evandro D Bezerra, F. Farrukh, Kristen B. McCullough, A. Al-Kali, H. Alkhateeb, K. Begna, M. Litzow, W. Hogan, M. Shah, M. Patnaik, A. Tefferi, N. Gangat   +12 more
semanticscholar   +1 more source

Oral hypomethylating agents: beyond convenience in MDS

Hematology, 2021
AbstractOral hypomethylating agents (HMAs) represent a substantial potential boon for patients with myelodysplastic syndrome (MDS) who have previously required between 5 and 7 visits per month to an infusion clinic to receive therapy. For patients who respond to treatment, ongoing monthly maintenance visits represent a considerable burden to quality of
openaire   +3 more sources

Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study [PDF]

, 2012
INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML.
Berdel, Wolfgang E., Brandts, Christian Hubertus, Bug, Gesine, Büchner, Thomas, Dührsen, Ulrich, Ehninger, Gerhard, Gerss, Joachim, Koschmieder, Anja, Koschmieder, Steffen, Krug, Utz, Müller-Tidow, Carsten, Noppeney, Richard, Röllig, Christoph, Schaich, Markus, Schwammbach, Daniela, Serve, Hubert, Steffen, Björn, Stelljes, Matthias, Thiede, Christian, Tidow, Nicola   +19 more
core   +3 more sources

Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes.

Clinical Lymphoma, Myeloma & Leukemia, 2022
INTRODUCTION/BACKGROUND Therapy with infused or injected hypomethylating agents (HMAs) may lead to higher treatment administration burden (ie, local reaction, visit frequency and duration) vs. oral HMAs.
A. Zeidan, Jui-Hua Tsai, M. Karimi, J. Schmier, Sayeli Jayade, E. Zormpas, A. Hassan, Desiree Ruiters, C. Anthony, Kala Hill, T. Wert, M. Botteman   +11 more
semanticscholar   +1 more source

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia [PDF]

Cell Cycle, 2011
The deregulation of the DNA damage response (DDR) can contribute to leukemogenesis and favor the progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML). Since hypomethylating agent, notably azacitidine, constitute an efficient therapy for patients with high-risk MDS, we assessed whether such compounds can activate the DDR in ...
Thépot, Sylvain, Lainey, Elodie, Cluzeau, Thomas, Sébert, Marie, Leroy, Carole, Adès, Lionel, Tailler, Maximilien, Galluzzi, Lorenzo, Baran-Marszak, Fanny, Roudot, Hervé, Eclache, Virginie, Gardin, Claude, de Botton, Stéphane, Auberger, Patrick, Fenaux, Pierre, Kroemer, Guido, Boehrer, Simone   +16 more
openaire   +3 more sources

Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia

Biomarker Insights, 2019
Epigenetic alteration has been proposed to give rise to numerous classic hallmarks of cancer. Impaired DNA methylation plays a central role in the onset and progression of several types of malignancies, and DNA methylation is mediated by DNA ...
Kah Keng Wong, Charles H Lawrie, Tina M Green   +2 more
doaj   +1 more source

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis

Haematologica, 2010
Hypomethylating agents have recently been shown to improve the outcome of patients with myelodysplastic syndrome. A meta-analysis and systematic review was carried out of randomized controlled trials comparing treatment with hypomethylating agents to ...
Ronit Gurion, Liat Vidal, Anat Gafter-Gvili, Yulia Belnik, Moshe Yeshurun, Pia Raanani, Ofer Shpilberg   +6 more
doaj   +1 more source

Decitabine in the treatment of acute myeloid leukemia in elderly patients [PDF]

, 2014
Priya Malik, Amanda F CashenWashington University School of Medicine, St Louis, MO, USAAbstract: The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy. Decitabine, a DNA-hypomethylating
Cashen, Amanda F., Malik, Priya
core   +3 more sources